Closed Trial – status update SOLO-2 GINECO-OV227/ENGOT-OV21 Study of OLaparib in Ovarian Cancer Trial setting: Platinum Sensitive Relapsed High grade serous ovarian cancer with a BRCA mutation or high grade endometrioid cancer Study Design: A Phase III, Randomised, Double Blind, Placebo Controlled Sponsor(s): AstraZeneca Final No. of patients: 295 Timeline (first patient – trial closing): Aug 2013- Aug 2021 Publications: In submission Planned publications and substudies: To be discused at the SOLO-2 TSC meeting (June 3rd 6:30 am) SOLO-2 - GCIG June 1st 2017
Primary Endpoint presented at SGO on March 2017 SOLO-2 - GCIG June 1st 2017
Tomorrow , do not miss …. • M. Friedlander Oral presentation on QOL data • Poster discussion on Tolerability SOLO-2 - GCIG June 1st 2017
Recommend
More recommend